Gossamer Bio (NASDAQ:GOSS) stock rating reaffirmed by HC Wainwright

Gossamer Biography (NASDAQ:GOSS – Get Free Report)Its stock had a “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $10.00 price target on the stock.

Several other equities analysts have also recently commented on the stock. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. Goldman Sachs Group reissued a “buy” rating and set a $8.00 price objective on shares of Gossamer Bio in a report on Monday, June 17th. Finally, Oppenheimer began coverage on shares of Gossamer Bio in a report on Tuesday, June 25th. They set an “outperform” rating and a $9.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating. Gossamer Bio presently has an average rating of “Buy” and a consensus price target of $9.20, based on data from MarketBeat.com.

Get the latest report on GOSS

Bio Gossamer trading down 2.3%

Shares of NASDAQ GOSS opened at $0.86 on Friday. The stock has a market cap of $194.75 million, a price-to-earnings ratio of -0.81 and a beta of 1.93. The company has a 50-day simple moving average of $0.97 and a 200-day simple moving average of $0.94. The company has a debt-to-equity ratio of 7.37, a quick ratio of 7.13, and a current ratio of 7.13. Gossamer Bio has a 52 week low of $0.45 and a 52 week high of $1.60.

Insider trading at Gossamer Bio

In related news, CEO Faheem Hasnain purchased 372,000 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was purchased at an average price of $0.67 per share, for a total transaction of $249,240.00. Following the completion of the acquisition, the chief executive officer now owns 5,408,073 shares of the company’s stock, valued at approximately $3,623,408.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Corporate insiders hold 5.00% of the company’s stock.

Institutional investors are weighing in on Gossamer Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GOSS. Sivia Capital Partners LLC bought a new stake in Gossamer Bio in the 1st quarter worth $29,000. SG Americas Securities LLC bought a new stake in shares of Gossamer Bio in the first quarter valued at approximately $34,000. Choreo LLC acquired a new position in shares of Gossamer Bio in the second quarter valued at $46,000. Algert Global LLC bought a new position in Gossamer Bio in the second quarter valued at about $75,000. Finally, Sequoia Financial Advisors LLC boosted its holdings in Gossamer Bio by 27.2% in the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock valued at $84,000 after acquiring an additional 20,000 shares during the period. 81.23% of the shares are currently held by institutional investors.

Gossamer Bio Company Profile

(Get a free report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, a small molecule, inhaled, platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor receptor 1 and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Featured stories

Get news and reviews for Gossamer Bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gossamer Bio and related companies with MarketBeat.com’s FREE daily email newsletter.